Attovia
About Attovia
Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.
```xml <problem> Many immune-mediated diseases and cancers lack effective antibody-based therapeutics, hindering treatment options for patients. Existing treatments often fail to achieve sufficient efficacy due to limitations in target engagement and tissue penetration. </problem> <solution> Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology, utilizing its proprietary ATTOBODY platform to generate first-in-class and best-in-class multispecific antibodies. The ATTOBODY platform employs spatial positioning technology to achieve biparatopic target engagement, resulting in picomolar affinity and glue-like off-rates for enhanced potency. The platform's unconstrained engineering allows for the development of multispecific biologics with tunable half-lives, potentially enabling less frequent dosing in patients. Attovia's high-throughput, evolution-based discovery platform accelerates and de-risks therapeutics development, offering the potential to become the next-generation modality of choice. </solution> <features> - ATTOBODY platform enables the creation of bispecific and multispecific antibodies. - Spatial positioning technology achieves biparatopic target engagement. - Picomolar affinity and glue-like off-rates enhance potency. - Unconstrained engineering allows for tunable half-life. - High-throughput, evolution-based discovery platform accelerates development. </features> <target_audience> The primary target audience includes patients with immune-mediated diseases and cancer, as well as pharmaceutical companies seeking novel therapeutic modalities. </target_audience> ```
What does Attovia do?
Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.
Where is Attovia located?
Attovia is based in Fremont, United States.
When was Attovia founded?
Attovia was founded in 2023.
How much funding has Attovia raised?
Attovia has raised 165000000.
- Location
- Fremont, United States
- Founded
- 2023
- Funding
- 165000000
- Employees
- 34 employees
- Major Investors
- Goldman Sachs Asset Management